The Medicines and Healthcare products Regulatory Agency (MHRA) is developing a Patient Engagement and Public Involvement Strategy to improve how it communicates with patients and healthcare professionals about medicines and medical devices safety. This active policy includes consultations on safety communications, prescription-only medicine proposals (such as Codeine Linctus), and addressing patient concerns about regulatory decisions affecting them.
The MHRA’s strategy for Improving Safety Communications for 2024 to 2027.
The Medicines and Healthcare Products Regulatory Agency (MHRA) have launched a public consultation to propose reclassification of Codeine Linctus to prescription-only medicine.
The MHRA is reviewing its approach to engagement with healthcare professionals to improve the safety of medicines and medical devices.
The Medicines and Healthcare Products Regulatory Agency (MHRA) have launched a public consultation to propose reclassification of Codeine Linctus to prescription-only medicine.
The Medicines and Healthcare Products Regulatory Agency (MHRA) have launched a public consultation to propose reclassification of Codeine Linctus to prescription-only medicine.
The MHRA is reviewing its approach to engagement with healthcare professionals to improve the safety of medicines and medical devices.
The MHRA is reviewing its approach to engagement with healthcare professionals to improve the safety of medicines and medical devices.
We’re looking for views from patients and the public on how we engage with them.
We’re looking for views from patients and the public on how we engage with them.
In response to: MHRA Patient Involvement Strategy consultation
In response to: How should we engage and involve patients and the public in our work
In response to: How should we engage and involve patients and the public in our work
In response to: How should we engage and involve patients and the public in our work
Work is ongoing to address the comments and feedback from respondents to the consultation. Publication of our report on the consultation has been delayed in light of the Agency’s response during the ongoing coronavirus situation.
Work is ongoing to address the comments and feedback from respondents to the consultation. Publication of our report on the consultation has been delayed in light of the Agency’s response during the ongoing coronavirus situation.
Work is ongoing to address the comments and feedback from respondents to the consultation. Publication of our report on the consultation has been delayed in light of the Agency’s response during the ongoing coronavirus situation.
The MHRA is asking for feedback on a proposal to allow wider access to naloxone for the purpose of saving life in an emergency.
The MHRA is asking for feedback on a proposal to allow wider access to naloxone for the purpose of saving life in an emergency.